SCHEMBL3662679

SCHEMBL3662679

CCOC(=O)N1CCn2c(nc(-c3ccncn3)cc2=O)C(NC(=O)c2ccc(C(F)(F)F)cc2OC)C1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 11/20 0.44
CYP2D6 P10635 3/20 0.36
CYP1A2 P05177 2/20 0.36
TRPC3 Q13507 1/20 0.36
TRPC7 Q9HCX4 1/20 0.36
KDR P35968 2/20 0.35
TEK Q02763 2/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
HPGD P15428 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 1/20 0.35
BTK Q06187 1/20 0.34
SLC6A9 P48067 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3662447 0.90 GSK3B (0.45) GSK3BCYP2D6CYP1A2
SCHEMBL3664584 0.89 GSK3B (0.46) GSK3BCYP2D6CYP1A2
SCHEMBL2064589 0.88 GSK3B (0.39) GSK3BCYP2D6CYP1A2KDRTEK
SCHEMBL3659037 0.86 GSK3B (0.43) GSK3BCYP2D6CYP1A2TRPC3TRPC7
SCHEMBL3665691 0.86 GSK3B (0.45) GSK3BCYP2D6CYP1A2
SCHEMBL1168937 0.82 GSK3B (0.46) GSK3BHPGDSMN1; SMN2ALDH1A1
SCHEMBL3664429 0.82 GSK3B (0.43) GSK3BCYP2D6HPGDSMN1; SMN2ALDH1A1
SCHEMBL3667749 0.81 HPGD (0.40) GSK3BHPGDSMN1; SMN2ALDH1A1
SCHEMBL3654635 0.81 GSK3B (0.46) GSK3BCYP2D6HPGDALDH1A1
SCHEMBL1168730 0.79 GSK3B (0.44) GSK3BCYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2238141-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA Sanofi-Aventis (FR) 2010-10-13 EP claimed
WO-2009095789-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA SANOFI-AVENTIS (FR) 2009-08-06 WO claimed
EP-2238141-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA Sanofi-Aventis (FR) 2010-10-13 EP disclosed
WO-2009095789-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA SANOFI-AVENTIS (FR) 2009-08-06 WO disclosed